Trans Genic Inc. (2342) AI Stock Analysis

• Market Cap: ¥3.73B
• Dividend Yield: 1.84%
• Average Volume (3M): 381.56K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.58
• Revenue Growth: 5.00%
• EPS Growth: -458.79%
• Country: JP
• Employees: 236
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 1.62
• Shares Outstanding: 16,999,142
• 10 Day Avg. Volume: 140,230
• 30 Day Avg. Volume: 381,563
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥198.00
• Price Target Upside: -7.91% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 56 Neutral
• Price Target: ¥198.00 ▼(-7.91% Downside)

The overall stock score is primarily influenced by the company's financial challenges, including negative profitability and cash flow issues. Despite these financial concerns, the stock's technical indicators show positive momentum, which provides some support to the score. However, the negative P/E ratio and lack of dividend yield weigh heavily on the valuation, resulting in a moderate overall score.

Trans Genic Inc. Business Overview & Revenue Model

Company Description

Trans Genic Inc. (2342) is a biotechnology company specializing in the development and commercialization of innovative genetic products and technologies. The company operates primarily in the agricultural and healthcare sectors, focusing on genetically modified organisms (GMOs) that enhance crop yields and improve resistance to pests and diseases. Additionally, Trans Genic Inc. offers biopharmaceutical solutions, including genetically engineered proteins and antibodies that address various medical conditions. With a strong emphasis on research and development, the company aims to lead advancements in genetic engineering and sustainable practices.

How the Company Makes Money

Trans Genic Inc. generates revenue through multiple streams, primarily from the sale of genetically modified seeds and crops to agricultural producers, which constitute a significant portion of its income. The company also earns revenue from licensing its genetic technologies to other firms in the biotechnology and agricultural sectors. Furthermore, Trans Genic Inc. collaborates with pharmaceutical companies to develop biopharmaceutical products, sharing profits from the sale of these products. Strategic partnerships with research institutions and universities enhance its R&D capabilities, potentially leading to novel products and revenue opportunities. The company may also benefit from government grants and subsidies aimed at promoting agricultural innovation and biotechnology research.

Trans Genic Inc. Financial Statement Overview

Summary

Trans Genic Inc. is facing significant financial challenges, particularly in maintaining revenue growth and profitability. The balance sheet remains relatively stable, but cash flow issues persist, impacting overall financial health. The company needs to address cost management and cash generation to improve its financial standing.

Income Statement

Trans Genic Inc. has experienced fluctuating revenue growth, with a recent decline in total revenue from the previous year. The company has faced challenges in maintaining profitability, as indicated by negative EBIT and net income in the latest period. The gross profit margin has decreased significantly from previous years, reflecting potential cost management issues.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, suggesting a balanced approach to leverage. However, the return on equity has turned negative due to recent net losses, indicating challenges in generating returns for shareholders. The equity ratio remains stable, showing a solid equity base relative to total assets.

Cash Flow

The cash flow statement reveals volatility in operating cash flows, with a recent positive shift. However, free cash flow remains negative, indicating ongoing challenges in generating surplus cash after capital expenditures. The operating cash flow to net income ratio is positive, suggesting some efficiency in cash generation relative to reported losses.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.01B	13.08B	11.43B	12.58B	11.05B
Gross Profit	2.17B	2.25B	1.99B	3.84B	2.78B
EBITDA	-397.56M	240.95M	-119.83M	3.02B	975.06M
Net Income	-1.09B	4.08M	-409.67M	1.88B	546.29M
Balance Sheet
Total Assets	9.59B	9.81B	10.67B	10.44B	8.92B
Cash, Cash Equivalents and Short-Term Investments	2.56B	2.48B	3.46B	4.62B	3.03B
Total Debt	2.58B	2.26B	2.42B	1.82B	2.00B
Total Liabilities	4.73B	3.81B	4.55B	3.80B	3.88B
Stockholders Equity	4.76B	5.89B	6.02B	6.53B	4.92B
Cash Flow
Free Cash Flow	-81.35M	-658.12M	-1.74B	1.26B	1.08B
Operating Cash Flow	94.10M	-392.45M	-1.43B	1.79B	1.22B
Investing Cash Flow	-287.85M	-280.93M	-216.02M	981.87M	48.43M
Financing Cash Flow	265.10M	-342.69M	484.98M	-1.18B	10.04M

Trans Genic Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 215.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:2342, the sentiment is Neutral. The current price of 215 is below the 20-day moving average (MA) of 225.40, above the 50-day MA of 212.78, and above the 200-day MA of 185.60, indicating a neutral trend. The MACD of 0.48 indicates Positive momentum. The RSI at 46.85 is Neutral, neither overbought nor oversold. The STOCH value of 21.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:2342.

Trans Genic Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2342	56 Neutral	¥3.73B	―		1.84%	5.00%	-458.79%
4594	56 Neutral	7.69B	-5.72	-124.45%	―	1254.76%	33.94%
4884	54 Neutral	3.40B	-3.39	0.00%	―	-8.56%	-7.26%
4881	38 Underperform	4.42B	-2.60	0.00%	―	965.85%	-42.78%
4591	37 Underperform	4.85B	-4.09	0.00%	―	-59.53%	11.70%
4598	28 Underperform	6.22B	-3.16	0.00%	―	0.00%	20.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%